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Abstract
The serotonin 5-hydroxytryptamine 3 receptor (5-HT3R) plays a unique role within the seven classes of the serotonin receptor
family, as it represents the only ionotropic receptor, while the other six members are G protein-coupled receptors (GPCRs). The
5-HT3 receptor is related to chemo-/radiotherapy provoked emesis and dysfunction leads to neurodevelopmental disorders and
psychopathologies. Since the development of the first serotonin receptor antagonist in the early 1990s, the range of highly selective
and potent drugs expanded based on various chemical structures. Nevertheless, on-off-targeting of a pharmacophore’s activity with
high spatiotemporal resolution as provided by photopharmacology remains an unsolved challenge bearing additionally the opportu-
nity for detailed receptor examination. In the presented work, we summarize the synthesis, photochromic properties and in vitro
characterization of azobenzene-based photochromic derivatives of published 5-HT3R antagonists. Despite reported proof of prin-
ciple of direct azologization, only one of the investigated derivatives showed antagonistic activity lacking isomer specificity.
Introduction
5-Hydroxytryptamine (5-HT), commonly known as serotonin
[1,2] or enteramine [3,4], is a monoamine neurotransmitter and
hormone which is produced in the brain and in intestines and
regulates a large variety of physiological functions in the
mammalian central and peripheral nervous system [1,5]. In the
central nervous system (CNS), it modulates sleep–wake cycles,
emesis, appetite, mood, memory, breathing, cognition and
numerous other functions [6-9]. In the gastrointestinal (GI)
tract, it causes peristalsis via either smooth muscle contraction
or enteric nerve depolarization [10]. It is also found in the
platelets, where it is presumably involved in blood coagulation
and vasoconstriction. Furthermore, serotonin is one of the
first neurotransmitters to appear during development [11] and
may have an organizing function in the development of
the mammalian CNS being involved in cell division, differ-
entiation, survival, neuronal migration [12,13] and synapto-
genesis [14]. Dysfunction of the 5-HT receptor (5-HTR)
signalling during early developmental stages my lead to altered
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cognitive ability, neurodevelopmental disorders, and increased
incidence of psychopathologies such as autism and schizo-
phrenia [15,16].
Serotonin operates via seven classes of 5-HT receptors of which
six are G protein-coupled receptors (GPCRs) and only one, the
5-HT3R, is a ligand-gated cation channel [5,6,17]. When this re-
ceptor was identified and cloned [18-20], it became clear that
5-HT3 takes a unique position as pentameric ligand-gated
cation-selective ion channel belonging to the Cys-loop receptor
subfamily. In vertebrates, this family also includes nicotinic
acetylcholine receptors (nAChRs), γ-aminobutyric acid type A
receptors (GABAARs), and glycine receptors (GlyRs). To date,
five subunits of the 5-HT3 receptor are identified (5-HT3A–5-
HT3E) [21]. Functional receptors are either constructed as
5-HT3A homopentamers or as heteropentamers containing
5-HT3A and 5-HT3B receptor subunits [22-24].
5-HT3 receptors are highly expressed in the brainstem, espe-
cially in areas involved in the vomiting reflex and in the dorsal
horn of the spinal cord [25]. These receptors are also expressed
presynaptically providing regulation of the neurotransmitters
release [21,22].
Besides targeting of 5-HT3Rs for the treatment of psychiatric
disorders, they are object to counteract postoperative nausea
and chemo-/radiotherapy provoked emesis [26-29]. In the early
1990s, the first potent and selective 5-HT3 receptor antagonist
ondansetron was initially developed [26]. Since then the devel-
opment of 5-HT3R antagonists progressed. The first-generation
antagonists are structurally categorized in three major classes:
(I) carbazole derivatives (e.g., ondansetron), (II) indazoles
(e.g., granisetron), and (III) indoles (e.g., dolasetron) [26,30].
Generally, 5-HT3R antagonists share a basic amine, a rigid
(hetero-)aromatic system and a carbonyl group or isosteric
equivalent which is coplanar to the aromatic system. Although
the antagonists show a general structural motive, they differ in
their binding affinities, dose responses, and side effects [22].
To improve prospective antagonists and obtain a systematic tool
for receptor investigation, spatial and temporal restriction of
ligand binding and concomitant activity regulation is desirable.
Fuelled by light, the growing field of photopharmacology
provides a noninvasive method to trigger a drug’s pharmacolog-
ical response on demand [31-33]. To introduce photorespon-
siveness into a biological system, different approaches are
feasible, e.g., the use of caged ligands (CL) [34-37], photo-
switchable tethered ligands (PTLs) [38-40], photoswitchable or-
thogonal remotely tethered ligands (PORTLs) [41] or photo-
chromic ligands (PCLs) [31,42]. The latter ones represent small
molecules, which can either be engineered via extension of the
chemical structure of a known pharmacophore towards a photo-
chromic moiety or via replacement of certain parts of the bio-
molecule to generate a photochromic hybrid biomolecule. In
this context, various photochromic scaffolds including
dithienylethenes, fulgi(mi)des, and azobenzenes are investigat-
ed [31,42]. The latter ones were already discovered in 1834 by
E. Mitscherlich [43] but it took around another 100 years till
G. S. Hartley [44] revealed their photo-induced trans–cis
isomerization representing the time of birth of the azobenzene
photoswitch. Benefiting of their accessible synthesis, large
change in polarity and geometry upon switching, excellent pho-
tochromic properties and tuneability, azobenzenes are amongst
the most widely used photochromic scaffolds [31,42,45-47].
Since their first use in a biological environment in the late
1960s for the photoregulation of the enzymatic activity of
chymotrypsin [48], their applications in biology widely
expanded towards receptor control [49-52] and fields as bacteri-
al growth [53], vision restoration [53-55], the respiratory chain
[56] and lipids [57,58]. Owing to the reported serotonin antago-
nists’ chemical structures, the use of azobenzene as photochro-
mic scaffold in the presented work seemed axiomatic. There-
fore, the primary design of our photochromic derivatives is
based on the direct “azologization” [59] of reported non-photo-
chromic antagonists [60,61] via replacement of the benzene-
ring connecting amide bond and thioether, respectively, by an
azo bridge.
Results and Discussion
Design and synthesis of azobenzene-based
photochromic modulators
The reported [60,61] scaffolds of 5-HT3R antagonists are based
on an aromatic system either connected to a purine/pyrimidine
moiety via a thioether bridge or a quinoxaline moiety via an
amide bond. Referring to this work performed by the groups of
DiMauro [60] and Jensen [61], we envisioned that the replace-
ment of the thioether or amide bond (Scheme 1) by an azo
bridge would result in highly active photochromic serotonin
5-HTR antagonists controllable by irradiation with light. Based
on the suggested receptor binding mode reported for one potent
non-photochromic antagonist (lead structure of 16c) [61] we ex-
pected the extended trans-isomer as biologically active configu-
ration whereas its bent cis-isomer should be inactive.
Synthesis of the quinoxaline-based
azobenzenes
The synthesis of the unsubstituted quinoxaline-based azoben-
zene derivatives 5a and 5b is based on a Baeyer [62]–Mills [63]
reaction (Scheme 2). Therefore, nitrosoquinoxaline 3 was
synthesized in a two-step procedure starting from 2-chloro-
quinoxaline (1), which was transformed into its oxime 2 using
hydroxylammonium chloride [64]. The subsequent oxidation
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Scheme 1: Approach of the direct azologization of reported [60,61] serotonin 5-HT3R antagonists via replacement of a thioether or amide bond by an
azo bridge.
Scheme 2: Synthesis of the differently substituted quinoxaline azobenzene derivatives 5a and 5b via Baeyer [62]–Mills [63] reaction [64,65].
Scheme 3: Synthesis of the methoxy-substituted quinoxaline derivative 12a via diazotization [66-69].
was performed using periodic acid as oxidant [65]. The subse-
quent reaction with differently substituted anilines in acetic acid
[65] provided both quinoxaline azobenzene derivatives in good
yields.
The methoxy-substituted quinoxaline azobenzene derivative
12a was synthesized via a different synthetic route depicted in
Scheme 3. In a first step, p-toluidine (4a) was diazotized using
sodium nitrite and subsequently reacted with the 2-chloroacetyl-
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Scheme 4: General procedure for the synthesis of purine- and thienopyrimidine-substituted arylazobenzenes and depiction of the corresponding
structures [70,71].
acetone ester derivative 7 providing hydrazine 8 [66]. Upon
reaction of the chloro-ester 8 with phenylenediamine (9) in the
presence of triethylamine the quinoxaline moiety was formed
[67]. Oxidation of the hydrazine derivative 10 using hydrogen
peroxide under an oxygen atmosphere afforded the quinoxaline
azobenzene derivative 11 [68]. Subsequent methylation using
methyl iodide [69] mainly resulted in the formation of the
N-methylated non-photochromic product 12b but in low yields
also the desired photochromic methoxy-substituted quinoxaline
azobenzene derivative 12a.
Synthesis of the purine and thienopyrimidine-
based derivatives
Scheme 4 depicts the general procedure applied for the synthe-
sis of differently substituted purine- and thienopyrimidine
azobenzene derivatives. Differently substituted non-photochro-
mic antagonists were chosen as lead structures delivering photo-
chromic derivatives with varying electronic and thus photochro-
mic properties. The respective arylamines 13a–c were con-
verted into their corresponding hydrazines 14a–c via di-
azonium-salt formation using sodium nitrite and subsequent
reduction using tin(II) chloride [70]. The following nucleo-
philic substitution at a chloro-substituted purine (15a,b) or
thienopyrimidine (15c), respectively, and subsequent oxidation
of the hydrazine moiety afforded the corresponding azobenzene
derivatives 16a–d [71].
Synthesis of azobenzene-extended thio-
purine derivatives
To further tune the photochromism and compare the properties
of direct azologization to azo-extension, two additional deriva-
tives of the in vitro most promising naphthalene azopurine 16c
were synthesized either by keeping the original thioether
(Scheme 5) or replacing it by an amide bond (Scheme 6) known
as common structural feature of 5-HT3R antagonists.
Scheme 5 reflects the synthesis of the azo-extended thiomethyl-
purine 23 starting with the synthesis of hydroxymethylazoben-
zene 19 [72] in a Baeyer [62]–Mills [63] reaction and subse-
quent nucleophilic substitution using cyanuric chloride (20)
[73] providing chloromethyl azobenzene 21. The introduction
of the thiopurine moiety in 23 was accomplished upon reaction
of 21 with dihydropurinethione 22 [74].
The amide-linked derivative of thiomethylpurine azobenzene 23
was synthesized via Baeyer [62]–Mills [63] formation of the
carboxylated azobenzene 25 starting from aminobenzoic acid
24 and nitrosobenzene (18) [75]. Activation using thionyl chlo-
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Scheme 5: Synthesis of the thiomethyl-linked purine azobenzene 23 [62,63,72-74].
Scheme 6: Synthesis of the amide-linked azobenzene purine 28 [62,63,75-77].
ride [76] afforded the acid chloride 26 and allowed amide-bond
formation [77] for the generation of 28 (Scheme 6).
Photochromic properties
The investigation of the photochromic properties of the poten-
tial 5-HT3R antagonists 5a, 5b, 12a, 16a–d, 23, and 28 was per-
formed in DMSO and depending on their solubility in phos-
phate buffer + 0.1% DMSO (16a–d) by UV–vis absorption
spectroscopy. The compounds were dissolved at 50 µM in the
respective solvent and irradiated with the indicated wave-
lengths to generate a substantial amount of their cis-isomer.
This process can be followed by a decrease of the trans-absorp-
tion maximum at around 350–400 nm and an increase in
absorption at around 450–500 nm in the UV–vis spectrum
representing the cis-isomer (Figure 1, black arrows). The
absorption bands of the trans and cis-isomers of compounds
12a, 16c, and 16d overlap to such an extent, that no new
maximum representing the cis-isomer was observed and thus
cis–trans isomerization only occurs thermally and is not trigger-
able by irradiation with visible light. Back-isomerization was
triggered by irradiation with visible light (5a, 5b, 16a, 16b, 23,
and 28) of the indicated wavelength or by thermal relaxation
(5a, 5b, 12a, 16a–d, 23, and 28). The irradiation times were de-
termined by following the UV–vis spectrum upon isomeriza-
tion until no more changes in absorption were observed and the
photostationary state (PSS) was reached. The points of intersec-
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Figure 1: UV–vis absorption spectra measured at 50 µM in DMSO. Left: purine derivative 16c; right: azo-extended derivative 23.
tion in the absorption spectrum upon switching (= isosbestic
points) indicate a clear two-component switching between trans
and cis-species without any degradation or formation of a side-
product (Figure 1, dotted black arrows). The UV–vis absorp-
tion spectra of all compounds are depicted in Supporting Infor-
mation File 1, Figures S1–S10 and the data are summarized in
Table S1 and Table S2. A comparison of the differently substi-
tuted purine azobenzene derivatives revealed the beneficial
effect of an o-chloro substitution on the photochromic proper-
ties of 16b compared to 16c as the electron density at the
nitrogen-rich purine core is reduced. Further reduction of the
electron density was achieved by using a thienopyrimidine
(16a) instead of a purine core (16b–d). Nevertheless, the photo-
chromic properties of those heterocyclic, especially purine-
based azobenzenes, are rather poor. In addition to direct azo-
logization, two azo-extended purine derivatives 23 and 28 were
synthesized resulting in excellent photochromic properties.
Figure 1 compares exemplarily the UV–vis absorption spectra
of the naphthalene-azo-purine 16c (left) and its azo-extended
azobenzene thioether purine 23 (right). The determination of the
thermal half-lives (THL) of the cis-isomers of compounds 5a,
5b, 12a, 16a–d, 23, and 28 was accomplished by monitoring the
increase in absorbance which corresponds to the evolution of
the trans-isomer after irradiation and exposure to dark. In
contrast to the heterocyclic compounds 5a, 5b, 12a, and 16a–d
with a thermal half-life in the seconds to minutes range, the azo-
extended compounds 23 and 28 showed only slow thermal
back-isomerization (day range) at room temperature. Depending
on the desired application, both properties may be of benefit.
For thermally instable compounds, only one wavelength for
switching is required. In case of thermally stable cis-isomers
constant irradiation to maintain a substantial amount of the cis-
isomer can be avoided.
Patch-clamp studies
The synthesized azo antagonist derivatives 5a, 5b, 12a, 16a–d,
23, and 28 were tested for their inhibitory activity using the
patch-clamp technique on heterologously expressed ionotropic
homopentameric 5-HT3A receptors. Only upon addition of 16c
the amplitude of the 5-HT3A mediated currents was decreased
(Figure 2, left). Application of a 50 µM solution of trans-16c in
its thermal equilibrium decreased the amplitude of 5-HT in-
duced currents on 54 ± 3% (n = 4). However, irradiation-in-
duced trans–cis isomerization with light of λ = 530 nm and
455 nm, respectively, had no significant effect on the amplitude
of 5-HT3A-mediated currents (Figure 2, right).
Conclusion
In the presented work, we address the design, synthesis, photo-
chromic characterization and in vitro investigation of in total
nine azobenzene-based derivatives of reported 5-HT3R antago-
nists. Initially, seven photoligands (5a, 5b, 12a, and 16a–d)
either based on quinoxaline (5a, 5b, and 12a) or purine deriva-
tives (16a–d) with varying electronic and thus photochromic
properties were synthesized by direct azologization of the
respective leads. Especially the purine-based azobenzenes
displayed high solubility in aqueous media. The beneficial
effect of substituents reducing the overall electron density of the
purine moiety (16a, 16b) resulted in higher photostationary
states and better band separation compared to 16c and 16d.
Still, only one compound (16c) showed antagonistic activity in
patch-clamp studies. This might be explained by the fact that its
corresponding non-photochromic lead is the inhibitory most
active reported [61] antagonist among the investigated ones.
The partial rigidization of the thioether via incorporation of an
azo bridge might result in a vast loss of activity. Thereby, azo-
logization of the less potent leads resulted in complete loss of
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Figure 2: On the left panel representative traces of currents induced by the application of 3 µM 5HT (black trace), by 3 µM 5HT and 50 µM trans-16c
(red trace), by 5HT and 16c under constant irradiation (455 nm, blue trace), and again by pure 5HT – wash-out of the studied compound (black trace)
are shown. On the right panel, a graph representing the relative amplitudes of currents in control (black column), at application of trans-16c (red
column), at application of 16c irradiated with blue light (blue column) and at wash-out (gray column) are shown. P > 0.05, paired t-test.
inhibitory activity (5a, 5b, 12a, 16a, 16b, 16d) and only the
originally most potent derivative 16c kept recordable antago-
nistic activity. The missing significant difference in activity
upon irradiation-induced trans–cis isomerization of 16c is prob-
ably due to its moderate photochromic properties and slow
trans–cis isomerization (Figure 1, left). During the patch-clamp
analysis, the cells are continuously superfused with external
solution resulting in a fast exchange of the surrounding media
and co-applied tested compounds. Thus, the cis-PSS of 16c
might not be reached by irradiation within the short time of
compound application despite continuous irradiation. Therefore,
two azobenzene-extended derivatives (23 and 28) with im-
proved photochromic properties were synthesized but lost
antagonistic activity probably due to their increased steric
demand.
In ongoing studies, detailed molecular modelling is used to
design potential photochromic antagonists fitting the require-
ments of the receptor’s binding pocket. Regarding the analysis
method, compounds will be optimized towards either thermally
stable cis-isomers to be tested separately upon prior irradiation
or faster switching compounds.
Supporting Information
Supporting Information File 1
Detailed photochromic characterization (UV–vis absorption
spectra, cycle performances, thermal half-lives) and NMR
spectra of all synthesized compounds are provided. The file
contains crystal structures of compounds 12b and 16a and
experimental procedures.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-15-74-S1.pdf]
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